Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938117 | 0.81 | IDO1 (0.46) | IDO1SLC6A2SLC6A4P2RX7CHRM5 | |
| SCHEMBL21403423 | 0.81 | IDO1 (0.46) | IDO1SLC6A2SLC6A4P2RX7CHRM5 | |
| SCHEMBL8415469 | 0.81 | IDO1 (0.46) | IDO1SLC6A2SLC6A4P2RX7CHRM5 | |
| SCHEMBL29875850 | 0.81 | IDO1 (0.46) | IDO1SLC6A2SLC6A4P2RX7CHRM5 | |
| SCHEMBL75416 | 0.81 | IDO1 (0.46) | IDO1SLC6A2SLC6A4P2RX7CHRM5 | |
| SCHEMBL295918 | 0.81 | IDO1 (0.50) | IDO1SLC6A2SLC6A4P2RX7CHRM5 | |
| Hydrochloric Acid SCHEMBL14157234 | 0.80 | IDO1 (0.49) | IDO1SLC6A2SLC6A4AGXTKIF11 | |
| SCHEMBL8883258 | 0.78 | CES2 (0.47) | IDO1 | |
| SCHEMBL13020830 | 0.78 | IDO1 (0.43) | IDO1SLC6A2SLC6A4P2RX7CHRM5 | |
| SCHEMBL13064739 | 0.78 | IDO1 (0.43) | IDO1SLC6A2SLC6A4P2RX7CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | claimed |
| EP-1150982-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha | CV THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6790958-B2 | ANTIPROLIFERATIVE AGENTS; FUNGICIDES | LUM ROBERT T (US) | 2004-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | IDO1 2053/4885SLC6A2 2872/4885SLC6A4 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.